bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
2.230
-0.070 (-3.04%)
At close: Apr 24, 2026, 4:00 PM EDT
2.240
+0.010 (0.45%)
After-hours: Apr 24, 2026, 7:57 PM EDT
bioAffinity Technologies Revenue
In the year 2025, bioAffinity Technologies had annual revenue of $6.16M, down -34.18%. bioAffinity Technologies had revenue of $1.59M in the quarter ending December 31, 2025, a decrease of -27.85%.
Revenue (ttm)
$6.16M
Revenue Growth
-34.18%
P/S Ratio
1.63
Revenue / Employee
$108,105
Employees
57
Market Cap
10.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.16M | -3.20M | -34.18% |
| Dec 31, 2024 | 9.36M | 6.83M | 269.68% |
| Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
| Dec 31, 2022 | 4.80K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Inotiv | 514.03M |
| MDxHealth | 107.88M |
| Biodesix | 88.50M |
| Exagen | 66.58M |
| XWELL | 29.21M |
| Precipio | 24.05M |
| iSpecimen | 1.93M |
| Mainz Biomed | 537.08K |
BIAF News
- 11 days ago - New Case Study: bioAffinity Technologies' CyPath® Lung Diagnostic Supports Physician's Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy - Business Wire
- 16 days ago - bioAffinity Technologies Transcript: Status update - Transcripts
- 18 days ago - bioAffinity Technologies' CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16 - Business Wire
- 24 days ago - bioAffinity Technologies' CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026 - Business Wire
- 4 weeks ago - bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice - Business Wire
- 5 weeks ago - New Case Study: bioAffinity Technologies' CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures - Business Wire
- 6 weeks ago - bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth - Benzinga
- 6 weeks ago - bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung - Business Wire